Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women’s health – specifically Novartis AG – due to the potential of...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.
South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
